Introduction
============

According to recent statistics in the United States, breast cancer is most common in women who are newly diagnosed with malignant tumors \[[@b1-crt-2017-508]\]. Although systemic treatment based on gene expression profiling has been generalized in clinics, breast cancer is still a leading overall cause of cancer deaths in women \[[@b1-crt-2017-508]\]. Regarding the wide spectrum of biological characteristics of the malignancy, current guidelines recommend different therapeutic approaches according to initial tumor extent and differential expression status of the hormone receptor and human epidermal growth receptor 2 (HER2) \[[@b2-crt-2017-508],[@b3-crt-2017-508]\]. Nevertheless, the potential of distant recurrence remains a major challenge in breast cancer. Advances in early radiological detection methods and novel chemotherapeutic drugs have improved the prognoses after distant tumor progression, but the median survival time of such cases ranges from a few months to approximately 3 years \[[@b4-crt-2017-508]\].

In a recent population-based analysis, approximately 7% of overall breast cancer patients developed distant metastasis \[[@b5-crt-2017-508]\]. The metastatic capacity is affected by the natural course of the disease and the intrinsic tendency of spreading tumor cells \[[@b6-crt-2017-508]\]. A more aggressive nature results in further tumor spread, which leads to differential long-term mortality \[[@b7-crt-2017-508]\]. Because conventional anti-cancer treatment is limited in eradicating the metastatic tumor cells completely, identifying high-risk patients who can benefit from an appropriate treatment of overt micrometastases is a priority. Considering the relatively longer survival duration of breast cancer patients, sufficiently long-term follow-up data are required for the outcome analysis.

Given the prior investigation of our institution \[[@b8-crt-2017-508]\], we evaluated the prognostic impact of initial failure types in breast cancer patients who underwent surgery plus postoperative radiotherapy (RT). Distinct time-course change patterns of mortality risk according to locoregional and distant recurrences were evaluated. Prognostic factors for distant metastasis were assessed, and a novel nomogram to predict the risk of distant tumor relapse was developed and validated. The present study was based on contemporary subtype-based systemic and/or endocrine treatments. Therefore, our scoring system may help to differentiate breast cancer patients with higher metastatic potential in a routine clinical evaluation.

Materials and Methods
=====================

1. Study population
-------------------

We analyzed a total of 1,181 breast cancer patients who completed surgery plus postoperative adjuvant RT at Seoul National University Bundang Hospital from January 2003 to December 2011. The eligibility criteria included: (1) initially M0 category, (2) no previous history of malignancy, (3) no refusal of systemic and/or endocrine treatment, and (4) at least 1 year of follow-up. Demographic and clinicopathological information with survival and recurrence data were collected from our medical records database.

2. Molecular subtypes and treatments
------------------------------------

We evaluated the expression status of estrogen receptor (ER), progesterone receptor (PR), HER2, and Ki-67 to determine molecular subtypes of luminal A (LA), luminal B (LB), HER2, and triple negative (TN), according to the 2013 St. Gallen Consensus criteria \[[@b9-crt-2017-508]\]. Given the immunohistochemistry (IHC) results, HER2-positive status was defined as: (1) c-erbB2 overexpression with an IHC score of 3, and (2) the presence of *HER2* gene amplification on fluorescence *in situ* hybridization with a c-erbB2 IHC score of 2. The expression of Ki-67 index was classified into a low (\< 14%) or high (≥ 14%) level. The definition of each subtype was as follows: LA for ER(+), PR(+), HER2(--), and a low level of Ki-67 index; LB for ER(+) with at least a high Ki-67 labeling index, PR(--), or HER2(+); HER2 for ER(--), PR(--), and HER2(+); TN for ER(--), PR(--), and HER2(--), respectively. The seventh edition of the American Joint Committee on Cancer (AJCC) staging system was used to assess primary tumor stage and lymph node status. For staging of patients with neoadjuvant chemotherapy prior to surgery, clinical T and N information was applied. All patients underwent curative surgery followed by postoperative adjuvant RT. Elective RT for supraclavicular or internal mammary nodal areas was determined based on the extent of nodal disease at diagnosis. Regarding the contemporary guideline based on molecular status and patient and/or tumor-related factors, clinicians determined the use of endocrine and/or HER2-targeted agents for each patient.

3. Follow-up data
-----------------

Post-treatment initial failure events were categorized as locoregional and distant metastatic recurrences. Locoregional recurrence was defined as recurred tumors at the ipsilateral breast/chest wall or regional lymphatics. Distant metastatic events included lymphatic spread other than ipsilateral regional lymph nodes, and tumor relapse beyond the locoregional sites, such as lung and/or pleura, visceral organs, bone, and the central nervous system.

4. Statistical analysis
-----------------------

Overall survival (OS) was defined as the time period between the start date of treatment and overall deaths. Post-progression survival (PPS) was the time interval between the diagnosis of initial tumor recurrence and overall deaths. Distant metastasis-free interval (DMFI) was estimated based on distant metastatic events as the first post-treatment failure. The Kaplan-Meier method and log-rank test were used to assess differential outcomes. The Cox proportional hazards model was used for multivariate analysis of DMFI. The proportional hazards assumptions were confirmed using logminus-log survival plots. Potentially significant factors to be included in multivariate analysis were selected applying the Akaike's Information Criteria \[[@b10-crt-2017-508]\]. According to the final set of the Cox regression model, a prognostic nomogram to predict risks of distant metastatic failure was developed. The accuracy of the prognostic model was evaluated using the concordance index. The calibration plot represented the predicted and actual 10-year probability of distant metastasis on the x- and y-axis, respectively, which was used to assess the calibration rate. Two-sided p-values \< 0.05 were considered statistically significant. SPSS ver. 22 (IBM Corp., Armonk, NY) and R ver. 3.2.3 (<https://www.r-project.org>) were used for all statistical analyses.

5. Ethical statement
--------------------

This study was approved by the Institutional Review Board (IRB) of our institution (IRB No: B-1505/298-116). The necessity of informed consent for this retrospective analysis was waived.

Results
=======

1. Patient characteristics
--------------------------

[S1 Table](#SD1-crt-2017-508){ref-type="supplementary-material"} presents the patient characteristics (n=1,181). Younger age (\< 45 years) was observed in 382 patients (32%). The LA, LB, HER2, and TN subtypes were verified in 38%, 33%, 10%, and 19% of the patients, respectively. T1, T2, T3, and T4 category was diagnosed in 615 (52%), 428 (36%), 102 (9%), and 36 (3%) patients, respectively, and node-positive disease was observed in 529 (45%) patients. Histologic grade III and presence of lymphovascular invasion were reported in 379 (32%) and 425 (36%) patients, respectively. Breast-conserving surgery and mastectomy were performed to 936 (79%) and 245 (21%) patients, respectively. In LA (n=446) and LB (n=384) groups, 439 (98%) and 362 (94%) patients were treated with endocrine treatment. Chemotherapy was administered in 928 patients (79%). Of them, adjuvant, neoadjuvant, and both adjuvant and neoadjuvant chemotherapy were administered in 664, 152, and 112 patients, respectively. Regarding the systemic treatment methods according to molecular subtypes, 53% and 12%, 71% and 24%, 68% and 41%, and 80% and 29% of LA, LB, HER2, and TN patients were treated with adjuvant and neoadjuvant chemotherapy, respectively. When the patients were categorized according to the year of diagnosis, such as "\< 2006 vs. ≥ 2006," "\< 2007 vs. ≥ 2007," and "\< 2008 vs. ≥ 2008," the proportion of adriamycin use was higher in patients who were diagnosed later in time (77% vs. 85%, 78% vs. 85%, and 78% vs. 86% with p=0.014, p=0.017, and p=0.001, respectively). However, the year of diagnosis (p=0.155, p=0.215, and p=0.524 on the basis of the year of 2006, 2007, and 2008, respectively) did not affect DMFI.

2. Outcome analysis
-------------------

The median follow-up duration was 76 months. When the patients were categorized according to the initial failure patterns, locoregional and distant metastatic recurrence was observed in 29 and 81 patients, respectively. The organ sites of distant tumor spread included: bone (n=28), lung and/or pleura (n=17), distant lymph nodes (n=12), liver (n=17), and brain and/or leptomeningeal seeding (n=7).

The 7-year OS rates for patients with no recurrence, locoregional recurrence, and distant metastasis were 99.1%, 67.6%, and 39.1%, respectively (p \< 0.001) ([Fig. 1A](#f1-crt-2017-508){ref-type="fig"}). The survival difference between the locoregional and distant recurrence groups was statistically significant (p=0.027). Estimating the survival time after recurred events, the 5-year rates of PPS were 54.2% and 33.5% for patients with locoregional recurrence and distant metastasis, respectively (p=0.043) ([Fig. 1B](#f1-crt-2017-508){ref-type="fig"}). Baseline hazard rate function plots of mortality according to the failure patterns are represented in [Fig. 2](#f2-crt-2017-508){ref-type="fig"}. In patients with distant metastasis, the mortality risk initially increased within 3 years, and the risk surge appeared again after 5 years of follow-up. However, in patients with locoregional recurrence, a relatively low and continuous risk increase was observed.

3. Prognostic factors for distant metastatic failure
----------------------------------------------------

[Table 1](#t1-crt-2017-508){ref-type="table"} shows the significant prognostic factors associated with DMFI. The 10-year percentages of DMFI were significantly different according to age (\< 45 years and ≥ 45 years; 88.1% and 94.4%, respectively; p=0.002), molecular subtypes (LA, LB, HER2, and TN; 96.8%, 91.1%, 86.5%, and 88.9%, respectively; p \< 0.001), T category (T1, T2-3, and T4; 98.1%, 86.8%, and 76.3%, respectively; p \< 0.001), N category (N0, N1, and N2-3; 98.0%, 92.0%, and 77.7%, respectively; p \< 0.001), histological grade (I-II and III; 92.7% and 90.4%, respectively; p \< 0.001), lymphovascular invasion (no and yes; 96.0% and 86.9%, respectively; p \< 0.001), types of primary surgery (breast-conserving and mastectomy; 96.3% and 77.5%, respectively; p \< 0.001), lymph node dissection (no and yes; 97.8% and 86.1%, respectively; p \< 0.001), and use of chemotherapy (no and yes; 98.8% and 90.5%, respectively; p \< 0.001). Given the result of univariate analysis, the multivariate Cox proportional hazards model indicated independently significant factors to be included in a prognostic nomogram as follows: age (\< 45 years vs. ≥ 45 years; hazard ratio \[HR\], 0.60; p=0.049), molecular subtypes (LA vs. LB, HER2, and TN; HR 2.25, 4.50, and 5.13, respectively; p=0.034, p=0.001, and p \< 0.001, respectively), T category (T1 vs. T2-3 and T4; HR, 2.27 and 3.68; p=0.023 and p=0.010, respectively), and N category (N0 vs. N1 and N2-3; HR, 3.44 and 6.98; p=0.043 and p=0.002, respectively).

[S2 Table](#SD2-crt-2017-508){ref-type="supplementary-material"} and [S3 Fig](#SD3-crt-2017-508){ref-type="supplementary-material"}. show the subgroup analysis of OS in patients with distant metastasis (n=81). Among the patient, tumor, and treatment-related variables, molecular subtypes (luminal, HER2, and TN; 84.6%, 60.0%, and 23.3%, respectively; p \< 0.001) and histological grade (I-II and III; 75.8% and 43.2%; p=0.005) were associated with different 5-year OS rates. However, other factors were not significant.

In terms of the timing of chemotherapy, the 10-year DMFI rates of adjuvant, neoadjuvant, and both adjuvant and neoadjuvant chemotherapy were 94.8%, 79.1%, and 79.2%, respectively, with statistical significances in paired comparisons of adjuvant vs. neoadjuvant (p \< 0.001) and adjuvant vs. both treatment (p \< 0.001) groups. However, the distribution of clinicopathologic characteristics was imbalanced according to the timing of chemotherapy. Patients with adjuvant chemotherapy had more favorable features in terms of T/N category and lymphovascular invasion ([S4 Table](#SD4-crt-2017-508){ref-type="supplementary-material"}).

4. A nomogram for predicting distant metastasis
-----------------------------------------------

Regarding the prognostic factors (age, molecular subtypes, T category, and N category), a prognostic nomogram for predicting distant metastatic failure after surgery plus postoperative RT was developed ([Fig. 3](#f3-crt-2017-508){ref-type="fig"}). The concordance index for this model was 0.812. The plot representing the predicted and actual Kaplan-Meier DMFI probability at 10 years shows the well-calibrated results ([Fig. 4](#f4-crt-2017-508){ref-type="fig"}).

5. Risk scores according to metastatic sites
--------------------------------------------

According to our nomogram, risk scores were calculated for each patient with distant metastasis. When the scores were compared between the groups of brain (n=7) vs. non-brain (n=74) metastases, the level of risk scores of patients with metastatic tumor spread to brain was significantly higher than the others (mean values of 21.5 vs. 17.8, respectively; p=0.029) ([Fig. 5](#f5-crt-2017-508){ref-type="fig"}).

Discussion
==========

This study evaluated differential OS and PPS according to locoregional and distant metastatic spread as the initial patterns of failure in breast cancer. The baseline hazard rate function plot of the distant metastasis group showed early and late mortality risk peaks, whereas there was a low and broad risk increment in cases of locoregional relapse. Regarding the prognostic implications of distant tumor progression, we constructed a nomogram to predict distant metastatic failure risk in contemporary clinical practice. Age, molecular subtypes, and T and N category at diagnosis were the independently associated determinants, and the nomogram was a well-validated model. Calculating total score points based on the nomogram, we observed higher level of risk scores with brain metastasis, in comparison with those of non-brain metastases.

We verified the poor prognostic impact of distant metastatic behavior on the long-term OS and PPS. As well as the intrinsic aggressiveness of metastatic tumor cells, limited systemic treatment options for clinical cure contribute to higher mortality risk after distant tumor progression \[[@b11-crt-2017-508]\]. Additionally, the distinct early and late risk peaks of overall deaths in patients with distant failure were different from the indolent pattern of risk increase in the group with locoregional recurrences. The short-term peak that emerged within 3 years indicated the lethality and highly aggressive character of the tumor cells. In addition, the limited therapeutic effects or resistance to conventional systemic treatment under the palliative setting might increase death events even after 5 years of follow-up. Therefore, an early therapeutic intervention to eradicate overt micrometastases is important to improve long-term prognosis of breast cancer.

Nomograms are known as representative tools for calculating the probability of specific outcomes in individual patients \[[@b12-crt-2017-508]\]. The two-dimensional diagram consists of a set of statistically significant factors associated with the risk of an event of interest. In the clinical practice, the graphical format is used to predict the occurrence of events. In our previous institutional analysis of patients who completed curative locoregional treatments, tumor relapse at the primary breast/chest wall and regional lymphatic pathways were relatively low, whereas distant metastatic risk was significantly different according to major molecular subtypes \[[@b8-crt-2017-508]\]. Although other prior studies have analyzed long-term outcomes and failure patterns of breast cancer \[[@b13-crt-2017-508],[@b14-crt-2017-508]\], risk factors strongly affecting the development of distant metastasis are not completely understood. Therefore, we established a statistical model to identify patients who are susceptible to distant metastasis after completion of the multimodality treatment in breast cancer. Because this study included patients treated under the uniform and contemporary clinical practices, treatment strategies and post-treatment surveillance methods were consistent. Additionally, the present long-term data could sufficiently detect the late occurrence of recurred events. When estimating distant metastatic failure risks after subtype-based curative treatment, our nomogram provides guidance to an individual-based systemic approach for better prognosis in breast cancer.

It was expected that young age would be associated with a higher risk of failure in breast cancer, but its impact on long-term survival is still controversial \[[@b15-crt-2017-508]-[@b17-crt-2017-508]\]. In a large-scale institutional study, distant metastatic risk significantly decreased in patients older than 40 years, which was similar with our results \[[@b18-crt-2017-508]\]. The HR values for overall metastatic sites ranged from approximately 0.6-0.8 in ages \> 40 years, in comparison with the risk of those \< 40 years of age. The protective effect of old age on distant metastatic tumor progression might be because of age-induced changes of the host immune system or the tumor microenvironment involved in the migration of tumor cells \[[@b19-crt-2017-508],[@b20-crt-2017-508]\]. However, old age can be a disadvantageous factor in that more intensive systemic treatment is often not medically feasible because of poor performance status or combined medical comorbidities \[[@b21-crt-2017-508]\]. Because the present study population received systemic and/or endocrine therapy based on physicians' discretion and guidelines, this study suggests the adverse effects of young age associated with distant tumor dissemination.

On the basis of our prior analysis \[[@b8-crt-2017-508]\], the present prognostic nomogram showing the differential contribution of the molecular subtypes is an informative predictor of metastatic behavior. One interesting point was the different risk scores within the luminal tumors, between the LA and LB subtypes. Similarly, a study by Arriagada et al. \[[@b22-crt-2017-508]\] suggested that the PR status was an independent risk factor (relative hazard value of 0.8 for a higher PR level; p=0.003 in multivariate analysis) affecting the likelihood of metastatic dissemination. It has been suggested that more complicated categories beyond the major molecular subtypes exist in breast cancer \[[@b23-crt-2017-508]\]. Especially within the luminal tumors, heterogeneous characteristics in relation to biological aggressiveness and responsiveness to hormonal therapy have been observed \[[@b24-crt-2017-508]\]. We suggest that comprehensive information regarding the ER, PR, HER2, and Ki-67 status is needed to estimate the risk of distant tumor relapse. Although subclassification of LB-HER2(--) and LB-HER2(+) within the luminal tumors was not considered significantly prognostic in our nomogram, multi-institutional large-scale analysis is needed to assess the potential of differential risk level.

In recent years, cumulative development of brain metastasis has been estimated at approximately 10-30% of overall breast cancer \[[@b25-crt-2017-508]\]. As well as the aging of patient population, enhanced control of systemic tumor cells and radiologic imaging techniques also contributed to early detection of brain metastasis \[[@b26-crt-2017-508]\]. Nevertheless, brain metastasis is one of the fatal causes of death in breast cancer, showing the worst survival outcome in comparison with other metastatic sites \[[@b27-crt-2017-508]\]. In the similar context, our nomogram-based risk calculation demonstrated that patients with initial brain metastasis represented higher risk scores than those of the other metastatic sites. This result might be related to the heterogeneity in the propensity to metastatic dissemination within the patients with distant failure \[[@b28-crt-2017-508]\]. Nevertheless, due to the small number of initial brain metastasis events (n=7), our results should be interpreted with caution. Further studies need to elucidate the differential risk level within the patients with distant failure, suggesting the potential of brain metastasis.

This study has some limitations. Because of the retrospective design, the potential of selection bias cannot be excluded. Although our nomogram showed well-validated results, further validation using other institutional data are necessary. We excluded patients who refused their planned or recommended treatment, but the temporal change of chemotherapy regimens could not be adjusted. Beyond the clinicopathological prognostic factors, the impact of genomics data on differential prognosis of breast cancer has been reported in recent years \[[@b29-crt-2017-508]\]. Therefore, future prediction models need to integrate biological characteristics of tumor cells and the tumor microenvironment.

We evaluated differential prognostic implications according to initial patterns of failure in breast cancer patients undergoing surgery plus postoperative adjuvant RT. Distant metastatic tumor spread led to higher overall mortality, in comparison with locoregional relapse. Distinct early and late mortality risk peaks on baseline hazard rate function plots were characteristic of the patients who developed distant failures. On the basis of significant prognostic factors associated with DMFI, this study established a nomogram to predict the likelihood of individual metastatic behavior. The present analysis could be informative to identify a subset of patients with potential overt micrometastases, suggesting the need of personalized chemotherapeutic strategies. Close surveillance for metastatic failure should be considered for patients with relatively higher risk scores.
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###### 

Prognostic factors for distant metastasis-free interval

  Variable                            Univariate   Multivariate                       
  ----------------------------------- ------------ -------------- ------------------- ----------
  **Age (yr)**                                                                        
   \< 45                              88.1         0.002          1                   
   ≥ 45                               94.4                        0.60 (0.39-0.99)    0.049
  **Menopausal, status**                                                              
   Premenopausal                      91.2         0.141                              
   Perimenopausal or postmenopausal   94.1                                            
  **Molecular subtype**                                                               
   Luminal A                          96.8         \< 0.001       1                   
   Luminal B                          91.1                        2.25 (1.06-4.77)    0.034
   HER2                               86.5                        4.50 (1.78-11.40)   0.001
   Triple negative                    88.9                        5.13 (2.20-11.95)   \< 0.001
  **T category**                                                                      
   T1                                 98.1         \< 0.001       1                   
   T2-3                               86.8                        2.27 (1.12-4.58)    0.023
   T4                                 76.3                        3.68 (1.37-9.87)    0.010
  **N category**                                                                      
   N0                                 98.0         \< 0.001       1                   
   N1                                 92.0                        3.44 (1.04-11.37)   0.043
   N2-3                               77.7                        6.98 (2.06-23.62)   0.002
  **Histologic grade**                                                                
   I-II                               92.7         \< 0.001       1                   
   III                                90.4                        0.76 (0.43-1.32)    0.329
  **Lymphovascular invasion**                                                         
   No                                 96.0         \< 0.001       1                   
   Yes                                86.9                        1.23 (0.71-2.14)    0.466
  **Primary surgery**                                                                 
   Breast-conserving                  96.3         \< 0.001       1                   
   Mastectomy                         77.5                        1.21 (0.41-3.59)    0.733
  **Lymph node surgery**                                                              
   No ALND                            97.8         \< 0.001       1                   
   ALND                               86.1                        1.05 (0.36-3.09)    0.933
  **Chemotherapy**                                                                    
   No                                 98.8         \< 0.001       1                   
   Yes                                90.5                        0.83 (0.23-2.99)    0.778

HR, hazard ratio; CI, confidence interval; HER2, human epidermal growth factor receptor 2; ALND, axillary lymph node dissection.
